These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. Ismail N; Omar SV; Ismail NA; Peters RPH J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087 [TBL] [Abstract][Full Text] [Related]
4. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174 [TBL] [Abstract][Full Text] [Related]
5. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. Snobre J; Villellas MC; Coeck N; Mulders W; Tzfadia O; de Jong BC; Andries K; Rigouts L Sci Rep; 2023 Jun; 13(1):10444. PubMed ID: 37369740 [TBL] [Abstract][Full Text] [Related]
6. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. Xu J; Li D; Shi J; Wang B; Ge F; Guo Z; Mu X; Nuermberger E; Lu Y Antimicrob Agents Chemother; 2023 Jul; 67(7):e0153222. PubMed ID: 37255473 [TBL] [Abstract][Full Text] [Related]
7. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270 [TBL] [Abstract][Full Text] [Related]
8. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Sonnenkalb L; Carter JJ; Spitaleri A; Iqbal Z; Hunt M; Malone KM; Utpatel C; Cirillo DM; Rodrigues C; Nilgiriwala KS; Fowler PW; Merker M; Niemann S; Lancet Microbe; 2023 May; 4(5):e358-e368. PubMed ID: 37003285 [TBL] [Abstract][Full Text] [Related]
9. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800 [TBL] [Abstract][Full Text] [Related]
10. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Hartkoorn RC; Uplekar S; Cole ST Antimicrob Agents Chemother; 2014 May; 58(5):2979-81. PubMed ID: 24590481 [TBL] [Abstract][Full Text] [Related]
11. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727 [TBL] [Abstract][Full Text] [Related]
12. Sub-MIC levels of bedaquiline and clofazimine can select Villellas C; Stevenaert F; Remmerie B; Andries K Antimicrob Agents Chemother; 2024 Apr; 68(4):e0127523. PubMed ID: 38470194 [TBL] [Abstract][Full Text] [Related]
13. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan. Ghodousi A; Rizvi AH; Baloch AQ; Ghafoor A; Khanzada FM; Qadir M; Borroni E; Trovato A; Tahseen S; Cirillo DM Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262765 [TBL] [Abstract][Full Text] [Related]
14. Genetic variants and their association with phenotypic resistance to bedaquiline in Ismail N; Rivière E; Limberis J; Huo S; Metcalfe JZ; Warren RM; Van Rie A Lancet Microbe; 2021 Nov; 2(11):e604-e616. PubMed ID: 34796339 [TBL] [Abstract][Full Text] [Related]
15. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis. Nimmo C; Ortiz AT; Tan CCS; Pang J; Acman M; Millard J; Padayatchi N; Grant AD; O'Donnell M; Pym A; Brynildsrud OB; Eldholm V; Grandjean L; Didelot X; Balloux F; van Dorp L Genome Med; 2024 Feb; 16(1):34. PubMed ID: 38374151 [TBL] [Abstract][Full Text] [Related]
16. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202 [TBL] [Abstract][Full Text] [Related]
17. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Richard M; Gutiérrez AV; Viljoen A; Rodriguez-Rincon D; Roquet-Baneres F; Blaise M; Everall I; Parkhill J; Floto RA; Kremer L Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323043 [TBL] [Abstract][Full Text] [Related]
18. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. Saeed DK; Shakoor S; Razzak SA; Hasan Z; Sabzwari SF; Azizullah Z; Kanji A; Nasir A; Shafiq S; Ghanchi NK; Hasan R BMC Microbiol; 2022 Feb; 22(1):62. PubMed ID: 35209842 [TBL] [Abstract][Full Text] [Related]
19. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706 [TBL] [Abstract][Full Text] [Related]
20. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]